Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05438836 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

Study acronym: ROAR-A
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 25, 2023 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 2 to Not specifiedv3
  2. Primary endpoint revised
    • Eligibility criteria revised
    • Secondary endpoints revised (8)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Trial Details
NCT Number NCT05438836
Lead Sponsor Herlev Hospital
Conditions
(from sponsor)		 Anal Cancer, Anal Carcinoma, Anal Squamous Cell Carcinoma
Related terms Anus Neoplasms
Enrollment 205 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov